Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04206020 · ClinicalTrials.gov registry record · Phase 3
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
A Phase 3 study of Dry Eye Syndrome, sponsored by Mitotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 610
- Enrollment target
- 4
- Study locations
NCT04206020 is a Phase 3 study of Dry Eye Syndrome that has completed, run by Mitotech. The registered enrollment target is 610 participants, above the 104-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (487% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT04206020, a Phase 3 study of Dry Eye Syndrome, has completed, sponsored by Mitotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 610 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.
Conditions Studied
Interventions
- DRUG SkQ1 Vehicle Solution
- DRUG SkQ1 Ophthalmic Solution
Study Locations (4)
Arizona
- Arizona Eye Institute and Cosmetic Laser - Sun City West
Massachusetts
- Andover Eye Associates - Andover
Texas
- Eye Clinics of South Texas - San Antonio
Virginia
- Piedmont Eye Center - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2020-10-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04206020
The ClinicalTrials.gov registry entry for NCT04206020 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 610 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 104-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (487% higher). The listed sponsor is Mitotech, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Syndrome appearing as the primary indexed condition, and to 2 interventions - of which SkQ1 Vehicle Solution is the first listed.
NCT04206020 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT04206020 about?
NCT04206020 is a clinical study titled "Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome". The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.
What is the current status of trial NCT04206020?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 610 participants. The study started on 2019-12-20. Estimated completion is 2020-10-06.
What conditions does trial NCT04206020 study?
This clinical trial studies the following conditions: Dry Eye Syndrome.
What interventions are being tested in trial NCT04206020?
The interventions under investigation include: SkQ1 Vehicle Solution (DRUG), SkQ1 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04206020?
This trial is sponsored by Mitotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04206020 being conducted?
This trial has 4 study locations across Arizona, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SkQ1 as Treatment for Dry-eye Syndrome
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
RECRUITING · Phase 1
-
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
COMPLETED · NA
-
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
COMPLETED · Phase 2
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
COMPLETED · Phase 1
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.